Aktis Oncology, Inc.
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q3 24 | Q4 24 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +19.1% | -5.5% | -14.6% | -12.0% | -8.3% | +228.6% | -3.2% | -14.5% | -5.1% | +117.8% | -3.3% | |
| – | +13.1% | -12.3% | -35.5% | -32.6% | +9.8% | +1,004.3% | -4.6% | -17.1% | -7.7% | +136.2% | -3.6% | |
| – | +13.3% | -18.3% | -40.2% | -50.1% | +18.1% | +1,377.9% | -83.5% | +385.1% | -79.0% | +883.6% | -77.8% | |
| – | +13.3% | -18.3% | -40.2% | -50.1% | +18.1% | +1,955.4% | -4.9% | -17.1% | -7.9% | +137.4% | -3.9% | |
| – | +33.9% | +11.9% | -17.1% | +53.8% | -8.1% | +26.2% | – | – | – | – | +4.5% | |
| – | +30.2% | -0.1% | -18.1% | -11.4% | -6.8% | -37.9% | – | – | – | – | – | |
| – | +80.5% | +0.2% | +0.0% | +0.0% | -55.3% | +0.0% | – | – | – | – | – | |
| – | +92.2% | -4.1% | -4.7% | -4.5% | -4.7% | -9.9% | – | – | – | – | – | |
| – | +7.3% | +9.9% | -5.3% | -2.1% | +4.4% | +581.9% | +0.0% | -0.6% | -0.1% | -82.8% | +2.9% | |
| – | +34.6% | +48.8% | -9.5% | -10.2% | +27.6% | -6.7% | +10.7% | +43.0% | +16.1% | -10.6% | +15.1% | |
| – | +53.1% | +5.8% | +4.8% | +3.9% | +126.5% | -31.4% | -12.8% | +5.5% | -3.8% | +8.7% | +3.4% | |
| – | +20.1% | +27.3% | +51.4% | -47.1% | +50.5% | -85.4% | +173.2% | +23.3% | -26.5% | -29.4% | +106.4% | |
| – | +27.0% | -14.2% | -21.4% | -20.7% | -22.1% | -283.2% | – | – | – | – | -4.2% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +18.4% | +5.2% | +0.8% | +1.1% | +24.9% | +69.2% | -66.0% | +0.0% | +1.7% | +3.5% | +0.1% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.